Sign in
4

Changes in Ownership

Monopar Therapeutics Filed Acc 0001437749-26-035039

Director sold 4,090 shares at an average $70.92 ($290,062)

  • Director acquired 4,090 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Tsuchimoto Kim R · Director

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2026-11-02 Exercise or conversion : show line 1 in the form 10b5-1 +1,199 $30.00 $35,970 1,199 D
2026-11-02 Sale : show line 2 in the form 10b5-1 −1,199 $70.10 $84,050 0 D
2026-11-04 Exercise or conversion : show line 3 in the form 10b5-1 +856 $30.00 $25,680 856 D
2026-11-04 Exercise or conversion : show line 4 in the form 10b5-1 +2,035 $14.00 $28,490 2,891 D
2026-11-04 Sale : show line 5 in the form 10b5-1 −1,295 $70.75 $91,621 1,596 D
2026-11-04 Sale : show line 6 in the form 10b5-1 −996 $71.35 $71,065 600 D
2026-11-04 Sale : show line 7 in the form 10b5-1 −600 $72.21 $43,326 0 D
Open-market sales · 4,090 sh · avg $70.92 · $290,062

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2026-11-02 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option −1,199 4,966 D
2026-11-04 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option −856 4,110 D
2026-11-04 Exercise or conversion : show line 10 in the form 10b5-1 Stock Option −2,035 6,105 D
Loading xslF345X06/rdgdoc.xml…